Drug-Drug Interaction Potential with Once-Weekly Isoniazid/Rifapentine (3HP) for the Treatment of Latent Tuberculosis Infection. (2022)

First Author: Marzolini C
Attributed to:  Liverpool COVID-19 Drug Interactions (www.covid19-druginteractions.org) funded by COVID

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1007/s40262-021-01098-8

PubMed Identifier: 34905153

Publication URI: http://europepmc.org/abstract/MED/34905153

Type: Journal Article/Review

Volume: 61

Parent Publication: Clinical pharmacokinetics

Issue: 3

ISSN: 0312-5963